Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Feb 26;18(1):116.
doi: 10.1186/s13256-024-04394-6.

Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report

Fatemeh Pourrezagholi  1 , Hossein Amini  2 , Omid Moradi  3 , Shadi Ziaie  4
Affiliations
Case Reports

Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report

Fatemeh Pourrezagholi et al. J Med Case Rep. .

Abstract

Background: In this manuscript, we report a case of tacrolimus-associated hepatotoxicity in a kidney transplant recipient.

Case presentation: In this case report, a 56 years old Arab male patient who received a kidney transplant presented with icterus, weakness, and lethargy two weeks after transplantation and tacrolimus initiation. In laboratory analysis hyperbilirubinemia and a rise in hepatic enzymes were observed. All possible causes of hepatotoxicity were examined. The panel for infectious causes was negative. Drug-induced liver injury was diagnosed. The patient's immunosuppressive regimen was changed to a cyclosporine-based regimen and after this change bilirubin and hepatic enzymes decreased and the patient was discharged without signs and symptoms of hepatitis.

Conclusion: It seems that the patient's hyperbilirubinemia was due to tacrolimus, and the patient's bilirubin decreased after stopping tacrolimus.

Keywords: Hepatotoxicity; Hyperbilirubinemia; Tacrolimus.

PubMed Disclaimer

Conflict of interest statement

The authors declared none.

Figures

Fig. 1
Fig. 1
Trend of total and direct bilirubin of the patient
See this image and copyright information in PMC

References

    1. Sanchez-Campos S, Lopez-Acebo R, Gonzalez P, Culebras JM, Tuñon MJ, Gonzalez-Gallego J. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation. 1998;66(1):84–88. doi: 10.1097/00007890-199807150-00013. - DOI - PubMed
    1. Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, Mamada Y, Yoshida H, Tajiri T. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nippon Med Sch. 2008;75(3):187–191. doi: 10.1272/jnms.75.187. - DOI - PubMed
    1. Hoofnagle JH, Björnsson ES. Drug-induced liver injury—types and phenotypes. N Engl J Med. 2019;381(3):264–273. doi: 10.1056/NEJMra1816149. - DOI - PubMed
    1. Ferjani H, El Arem A, Bouraoui A, Achour A, Abid S, Bacha H, Boussema-Ayed I. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats. J Physiol Biochem. 2016;72(2):133–144. doi: 10.1007/s13105-015-0451-7. - DOI - PubMed
    1. Vallet-Pichard A, Rerolle JP, Fontaine H, Larousserie F, Peraldi MN, Kreis H, Pol S. Veno-occlusive disease of the liver in renal transplant patients. Nephrol Dial Transplant. 2003;18(8):1663–1666. doi: 10.1093/ndt/gfg222. - DOI - PubMed

Publication types